公开(公告)号：EP3312287A1

公开(公告)日：2018-04-25

申请号：EP16811739.8

申请日：2016-06-17

Applicant: The Research Foundation for Microbial Diseases of Osaka University ,  Osaka University

Inventor： AKEDA, Yukihiro ,  MIYATAKE, Hiroshi ,  PIAO, Zhenyu ,  KOIZUMI, Yuka

IPC: C12Q1/02 ,  G01N33/15 ,  C07K16/12 ,  C12N1/20 ,  C12N5/078 ,  C12N5/0787

CPC classification number: C12Q1/18 ,  C07K16/12 ,  C12N1/20 ,  G01N2333/3156

Abstract: The present invention relates to a measurement method for complement-dependent bactericidal activity against Streptococcus pneumoniae, and provides a measurement method capable of measuring complement-dependent bactericidal activity against Streptococcus pneumoniae of any capsular serotype. Complement-dependent bactericidal activity against Streptococcus pneumoniae is measured using capsule-deficient Streptococcus pneumoniae, that is, non-encapsulated or substantially non-encapsulated, or transparent Streptococcus pneumoniae. The measurement of the complement-dependent bactericidal activity against Streptococcus pneumoniae of any capsular serotype is enabled.

Abstract translation: 本发明涉及针对肺炎链球菌的补体依赖性杀菌活性的测定方法，提供能够测定对任何荚膜血清型的肺炎链球菌的补体依赖性杀菌活性的测定方法。 使用缺乏胶囊的肺炎链球菌（即未包封的或基本上未包封的）或透明的肺炎链球菌来测量对肺炎链球菌的补体依赖性杀菌活性。 可以测量任何荚膜血清型对抗肺炎链球菌的补体依赖性杀菌活性。

公开(公告)号：EP3824891A1

公开(公告)日：2021-05-26

申请号：EP19837200.5

申请日：2019-07-18

Applicant: The Research Foundation for Microbial Diseases of Osaka University ,  Osaka University ,  Teikyo University

Inventor： AOSHI, Taiki ,  KOYAMA, Shohei ,  SUZUKI, Ryo

IPC: A61K31/7088 ,  A61K9/127 ,  A61K9/133 ,  A61K47/18 ,  A61K48/00 ,  A61P35/00 ,  A61P37/04

Abstract: An object is to provide a technology that can stably exhibit the effects of A-type CpG oligodeoxynucleotides. The object can be achieved by a lipid particle comprising an A-type CpG oligodeoxynucleotide.

公开(公告)号：EP2814841A1

公开(公告)日：2014-12-24

申请号：EP13744084.8

申请日：2013-01-31

Applicant: Osaka University ,  The Research Foundation for Microbial Diseases of Osaka University ,  Medical and Biological Laboratories Co., Ltd. ,  Department of Medical Sciences

Inventor： YASUGI, Mayo ,  KUHARA, Motoki ,  BOON-LONG, Jotika ,  FUJIYAMA, Kazuhito ,  KOKETSU, Ritsuko ,  IKUTA, Kazuyoshi

IPC: C07K16/10 ,  A61K39/395 ,  A61P31/16 ,  C12N15/02 ,  C12P21/08 ,  G01N33/569

CPC classification number: C07K16/1018 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/56983 ,  G01N2333/11

Abstract: Materials and methods are provided for treating influenza B infections in humans. Anti-human influenza virus monoclonal antibodies and antigen-binding fragments thereof having a neutralization activity against a human influenza B virus are provided. Methods for producing anti-human influenza B virus monoclonal antibodies are also provided. The antibodies and antigen-binding fragments thereof can be effective against a wide range of influenza B viral strains. Methods of inhibiting or treating a human influenza B infection are provided. The anti-influenza B therapeutics can also be used to manufacture medicaments effective against influenza B infections, to detect human influenza B in a human subject, for use in pharmaceutical compositions, and for use in kits for at least one of the prevention, the treatment, and the detection of human influenza B in a human subject.

公开(公告)号：EP2380976A1

公开(公告)日：2011-10-26

申请号：EP09834454.2

申请日：2009-12-24

Applicant: Osaka University ,  THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY ,  Benesis Corporation ,  Medical and Biological Laboratories Co., Ltd.

Inventor： IKUTA, Kazuyoshi ,  KOKETSU, Ritsuko ,  OKUNO, Yoshinobu ,  YUNOKI, Mikihiro ,  IDENO, Shoji ,  OSHITA, Masatoshi ,  KUHARA, Motoki ,  MOMOTA, Masatoshi

IPC: C12N15/00 ,  A61K39/395 ,  A61P31/16 ,  C07K16/10 ,  C12N15/09

CPC classification number: C07K16/1018 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/76

Abstract: Provided is a human antibody having a neutralization activity against a human influenza virus. More specifically, provided is a human antibody which recognizes a highly conserved region in a human influenza A virus subtype H3N2 or a human influenza B virus and has a neutralization activity against the virus. The human antibody is a human anti-human influenza virus antibody, which has a neutralization activity against a human influenza A virus subtype H3N2 and binds to a hemagglutinin HA1 region of the human influenza A virus subtype H3N2, or which has a neutralization activity against a human influenza B virus, and includes, as a base sequence of a DNA encoding a variable region of the antibody, a sequence set forth in any one of SEQ ID NOS: 5 to 12.

公开(公告)号：EP2443138A1

公开(公告)日：2012-04-25

申请号：EP10789227.5

申请日：2010-06-16

Applicant: Osaka University ,  THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY ,  Benesis Corporation ,  Medical and Biological Laboratories Co., Ltd. ,  Mitsubishi Tanabe Pharma Corporation

Inventor： IKUTA, Kazuyoshi ,  KOKETSU, Ritsuko ,  YAMASHITA, Akifumi ,  KAWASHITA, Norihito ,  YUNOKI, Mikihiro ,  OKUNO, Yoshinobu ,  IDENO, Shoji ,  KUHARA, Motoki

IPC: C07K14/11 ,  A61K39/145 ,  A61K39/395 ,  A61P31/16 ,  C07K16/10

CPC classification number: C07K16/1018 ,  A61K39/00 ,  A61K2039/55566 ,  A61K2039/6081 ,  C07K14/005 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/76 ,  C12N2760/16122

Abstract: Antigenic peptides are provided that can be used to induce global neutralizing antibodies, or antibodies reactive against a wide range of influenza A virus strains. The antigenic peptide can correspond to SEQ ID NO: 34 (EKEVLVLWG), SEQ ID NO: 2 (KFDKLYIWG), SEQ ID NO: 71(QEDLLVLWG), SEQ ID NO: 51 (EGRINYYWTLLEP), SEQ ID NO: 3 (PSRISIYWTIVKP), and/or SEQ ID NO: 82 (SGRMEFFWTILKP).

Abstract translation: 提供了可用于诱导全局中和抗体或抗多种甲型流感病毒株的抗体的抗原肽。 该抗原肽可对应于SEQ ID NO：34（EKEVLVLWG），SEQ ID NO：2（KFDKLYIWG），SEQ ID NO：71（QEDLLVLWG），SEQ ID NO：51（EGRINYYWTLLEP），SEQ ID NO：3（PSRISIYWTIVKP） ，和/或SEQ ID NO：82（SGRMEFFWTILKP）。

公开(公告)号：EP4527294A1

公开(公告)日：2025-03-26

申请号：EP25150857.8

申请日：2021-02-12

Applicant: OSAKA UNIVERSITY

Inventor： TAKEDA, Shuko ,  MORISHITA, Ryuichi

IPC: A61B5/16 ,  A61B5/00 ,  G16H10/20 ,  G16H30/40 ,  G16H50/20 ,  G16H50/30 ,  A61B3/113

Abstract: A cognitive impairment diagnostic device (1) includes: an obtainer (41) that obtains a distribution map representing a distribution of gaze points of a subject on a movie for cognitive assessment; and a diagnoser (39). The movie for cognitive assessment includes, in time order: a first movie including a first region including an image for encoding displayed in a visually enhanced manner, and a plurality of second regions including normal images displayed without being enhanced; and an assessment movie including a third region including an assessment image similar to the image for encoding and displayed at a same position as the image for encoding without being visually enhanced, and the second regions. The diagnoser (39) calculates, in a distribution map on the assessment movie, a percentage of fixation duration for which the third region is focused on, and makes diagnosis of suspected memory impairment when the percentage of fixation duration is lower than a threshold.

公开(公告)号：EP4495059A3

公开(公告)日：2025-03-26

申请号：EP24218136.0

申请日：2018-07-04

Applicant: OSAKA UNIVERSITY

Inventor： KOBAYASHI, Hikaru ,  KOBAYASHI, Yuki ,  IMAMURA, Ryoichi ,  NONOMURA, Norio

IPC: A61K33/00 ,  A61K9/56 ,  A61K47/04 ,  A61P9/10 ,  A61P13/12 ,  A61P39/06 ,  C01B3/08 ,  C01B33/02

Abstract: One drug (solid preparation) 100 of the present invention is a drug for a disease of kidney that contains a silicon fine particle, an aggregate of the silicon fine particles, or a crystal grain of silicon having a hydrogen-generating ability. Hydrogen generated from the silicon fine particle in the drug can contribute to the prevention and/or treatment of the kidney disease.

公开(公告)号：EP4516205A1

公开(公告)日：2025-03-05

申请号：EP24197251.2

申请日：2024-08-29

Applicant: OSAKA UNIVERSITY ,  TOPCON CORPORATION

Inventor： FUJIKADO, Takashi ,  TATARA, Yoko ,  YUKIMORI, Takafumi ,  SAIKA, Makoto ,  NORO, Ryoka

IPC: A61B3/08 ,  A61B3/103

Abstract: An ophthalmic examination apparatus (100) includes a visual target projection system (4) that includes a visual target presentation portion that presents a fixed visual target to left and right subject eyes (EL, ER), an objective measurement optical system (6, 7) that objectively measures eye characteristics of the left and right subject eyes (EL, ER), and a controller (140) that controls each portion of the apparatus, wherein the controller (140) measures the eye characteristics of the left and right subject eyes (EL, ER) with the objective measurement optical system (6, 7) and acquires an objective refraction value as objective measurement information when fusion is attempted with left and right subject eyes (EL, ER) with respect to a change in the convergence distance.

公开(公告)号：EP4491612A1

公开(公告)日：2025-01-15

申请号：EP23766793.6

申请日：2023-03-06

Applicant: OSAKA UNIVERSITY

Inventor： FUKASE Koichi ,  TOYOSHIMA Atsushi ,  SHINOHARA Atsushi ,  SHIRAKAMI Yoshifumi ,  KANEDA Kazuko ,  SHIMOYAMA Atsushi ,  KADONAGA Yuichiro

IPC: C07C231/12 ,  C07B59/00 ,  C25B3/11 ,  C25B3/27 ,  C25B15/023 ,  C25B15/029 ,  C25B15/08 ,  A61K51/00

Abstract: Provided is a novel method for labeling a radionuclide such as 211 At with a high radiochemical yield under more convenient and stable conditions.
A production method of an aryl compound labeled with a radionuclide includes a step of applying a voltage to a solution A containing a radionuclide and electrolytically oxidizing the radionuclide; and a step of mixing the solution A and a solution B containing a compound S having a halogenated aryl group to substitute a halogen atom on the aryl group of the compound S with the radionuclide.

公开(公告)号：EP4488361A1

公开(公告)日：2025-01-08

申请号：EP23774458.6

申请日：2023-03-03

Applicant: Toppan Holdings Inc. ,  OSAKA UNIVERSITY

Inventor： KITANO Shiro ,  MATSUSAKI Michiya ,  XIE Zhengtian

IPC: C12N5/00 ,  C07K14/78 ,  C12N11/00

Abstract: The present invention relates to a bioink containing a fragmented extracellular matrix component.